Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec 31:2:e108-e112.
doi: 10.5114/amsad.2017.72533. eCollection 2017.

Non-hemorrhage-related adverse effects of rivaroxaban

Eliza C Christopoulou  1 , Theodosios D Filippatos  1 , Moses S Elisaf  1
Affiliations

Non-hemorrhage-related adverse effects of rivaroxaban

Eliza C Christopoulou et al. Arch Med Sci Atheroscler Dis. .

Abstract

The direct oral anticoagulant rivaroxaban is useful in various indications that include venous deep vein thrombosis prophylaxis/treatment after knee/hip replacement surgery and prevention of stroke in patients with non-valvular atrial fibrillation. Its mechanism of action has been mostly associated with hemorrhage-related adverse effects; thus a number of non-hemorrhage-related adverse effects of the drug have received less attention or go unrecognized. These adverse effects mainly include liver injury, hypersensitivity reactions, leukocytoclastic vasculitis and hair loss. Clinicians should be aware of these rare adverse reactions and advise their patients to contact them as soon as they observe any unexpected clinical response.

Keywords: adverse effects; anaphylaxis; hair loss; hypersensitivity; liver; rivaroxaban; vasculitis.

PubMed Disclaimer

References

    1. Comerota AJ, Ramacciotti E. A comprehensive overview of direct oral anticoagulants for the management of venous thromboembolism. Am J Med Sci. 2016;352:92–106. - PubMed
    1. Bauer KA. Pros and cons of new oral anticoagulants. Hematol Am Soc Hematol Educ Program. 2013;2013:464–70. - PubMed
    1. Conway SE, Hwang AY, Ponte CD, Gums JG. Laboratory and clinical monitoring of direct acting oral anticoagulants: what clinicians need to know. Pharmacotherapy. 2017;37:236–48. - PubMed
    1. Xarelto Package Insert Available at: https://www.xareltohcp.com/shared/product/xarelto/prescribing-informatio.... Accessed at 11.11.2017.
    1. Xarelto EMEA Product Information Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medici.... Accessed at: 11.11.2017.

LinkOut - more resources